European Patient Cancer Coalition Publishes Patient Guide for Cancer Biomarkers
European Patient Cancer Coalition published Patient Guide for Cancer Biomarkers in January 2023.
European Patient Cancer Coalition published Patient Guide for Cancer Biomarkers in January 2023.
The LRG published "Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of Life Raft Group members" in BMC Gastroenterology, November 2022.
The Life Raft Group partnered with Dr. Michael Wagner of the University of Washington to present “The Importance of Biomarker Testing” to GIST patients and caregivers on August 12th, 2022.
The Life Raft Group is currently conducting a tissue testing initiative for GIST patients to receive FREE Next-Generation Sequencing (NGS) Testing!
In this webinar, there were case study presentations from three top sarcoma institutions that demonstrate the value of biomarker testing. A Question & Answer session followed the presentations.
The Life Raft Group (LRG) is providing you with this information to let you know that comprehensive genomic profiling, also known as biomarker testing or molecular testing, is a crucial step in understanding the genomic factors that play a role in a GIST diagnosis. Bayer Pharmaceuticals, in partnership with The Life Raft Group (LRG), has extended a research collaboration to broaden access to comprehensive genomic testing (CGT) for Gastrointestinal Stromal Tumor (GIST) patients.
This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.
So far in 2021, our 'It's Time' campaign has emphasized twelve important points concerning biomarker testing and the important role it plays in a GIST patient's journey. We will keep the momentum going with patient stories, webinars, and resource materials.
Biomarker testing is an opportunity to improve and optimize treatment. In this post, GISTer Bill Borwegen shares his story and we share how you can help save lives.
Identifying rare subsets of GIST and starting new clinical trials is critical. Read here about one researcher's clinical trial progress.